Optimal lung cancer care pathways: a Tasmanian perspective
Australian Health Review · 2025
DOI: 10.1071/ah24249 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australian Health Review, 2025. Verfasst von Chui Lyn Leong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Critical Pathways, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
In Australia, Tasmania has the second highest rate of incident lung cancer cases at 44.0 per 100,000 population, with an overall 5 year relative survival rate of 20%. The aim of this retrospective study was to map and compare patient transit timelines from referral, diagnosis and treatment, to national care quality indicators (NCQI) and optimal care pathway (OCP) benchmarks.
Methods
Data were extracted from the weekly lung cancer multidisciplinary team meeting minutes, digital medical records and the ARIA Oncology-Information System for newly diagnosed small cell and non-small cell lung cancer cases between 2019 and 2022, at a regional, university-affiliated tertiary hospital in Tasmania. Sociodemographic data and key dates were extracted, including first general practitioner (GP) referral, specialist appointments (respiratory, medical oncology, radiation oncology and cardiothoracic), investigations, diagnosis, staging and treatment of any intent. Timelines were benchmarked against NCQI and the OCP.
Results
A total of 165 cases were included; mean patient age was 72 years, and 57% were male. A total of 153 patients (93%) were diagnosed with non-small cell cancer and 12 (7%) with small cell lung cancer. Results for all years showed that 93% of patients were seen by the respiratory service within 14 days of their GP referral and 71% diagnosed within 28 days of their referral, in accordance with current standards. The time taken between GP referrals and diagnosis to any treatment was greater than the required standards, with on average 7% of patients meeting the quality standards (range, 0–16%) for all treatment intents.
Conclusion
Current national benchmarks have proven challenging to achieve, with prolonged time to treatment of any intent. Challenges both at a patient and systemic level will need to be assessed to improve clinical indicator outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Respiratory and Sleep Medicine, Royal Hobart Hospital, Tas 7000, Australia.
- Menzies Institute for Medical Research, University of Tasmania, Tas, Australia.
Zitieren
APA
Leong, C. L., Cox, I., Grundy, R., Harkness, N., Palmer, A. J., de Graaff, B., & Ball, E. (2025). Optimal lung cancer care pathways: a Tasmanian perspective. Australian Health Review. https://doi.org/10.1071/ah24249
Vancouver
Leong CL, Cox I, Grundy R, Harkness N, Palmer AJ, de Graaff B, et al. Optimal lung cancer care pathways: a Tasmanian perspective. Australian Health Review. 2025. doi:10.1071/ah24249
BibTeX
@article{Leong2025,
author = {Leong, Chui Lyn and Cox, Ingrid and Grundy, Renae and Harkness, Nick and Palmer, Andrew J and de Graaff, Barbara and Ball, Emma},
title = {Optimal lung cancer care pathways: a Tasmanian perspective},
journal = {Australian Health Review},
year = {2025},
doi = {10.1071/ah24249}
}
EUVIMED